A Phase 1, Randomized Double-Blind, Placebo-Controlled, Single Ascending Dose Safety, Tolerability, and Pharmacokinetics Study of SAB-301 in Healthy Adults

**Lead Associate Investigator:** John Beigel, MD
Leidos Biomedical Research, Inc. in support of Clinical Research Section, LIR, NIAID, NIH
Building 10, Rm 9N208D, Bethesda, MD 20892-1763
Phone: 301-451-9881; Email: jbeigel@niaid.nih.gov

**Principal Investigator:** Richard T. Davey, Jr., MD
Clinical Research Section, LIR, NIAID, NIH
Building 10, room 4-2179, Bethesda, MD 20892-1662
Phone: 301-496-8029; Email: rdavey@niaid.nih.gov

**Associate Investigator:**
Jocelyn Voell, RN, MS, LIR/NIAID/NIH, 301-435-7913, jvoell@niaid.nih.gov

**Research Contact:**
Jocelyn Voell, RN, MS, LIR/NIAID/NIH, 301-435-7913; jvoell@niaid.nih.gov

**IND Sponsor:**
Office of Clinical Research Policy and Regulatory Operations (OCRPRO), Division of Clinical Research (DCR), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH)
5601 Fishers Lane, Bethesda, MD 20892

**Sponsor Medical Monitor:**
H. Preston Holley, MD
Leidos Biomedical Research, Inc.
Phone: (301) 228-4005, Email: Preston.Holley@fnlcr.nih.gov

**IRB:**
NIAID IRB, 5601 Fishers Lane, Bethesda, MD 20892

**Study Site:**
NIH Clinical Center, Bethesda, MD 20892

**IND #:** 16918
**NIAID IRB version:** 2
**Protocol Number:** 16-I-0119
**Date:** November 1, 2016
CLINICAL LABORATORIES
NIH Clinical Laboratory, Bethesda, MD 20892

RESEARCH LABORATORIES
SAB Biotherapeutics, Sioux Falls, SD
Testing:
  • Anti-Drug (anti-SAB-301) Antibody
  • Anti-Bovine Kappa light chain
  • Anti- [redacted] Antibody
Primary collaborators:
  • Hua Wu, Ph.D. 2301 E 60th St N, Sioux Falls, SD 57104. hwu@sabbiotherapeutics.com

Naval Medical Research Center, Silver Spring, MD
Testing:
  • MERS micro-neutralization
Primary collaborators:
  • Kanakatte Ravipракash, Ph.D. 503 Robert Grant Ave. Silver Spring, MD 20910. kanakatte.s.ravipракash.civ@mail.mil
  • Thomas Luke, MD. 503 Robert Grant Ave. Silver Spring, MD 20910. thomas.c.luke.ctr@mail.mil

NIAID Integrated Research Facility, Frederick, MD
Testing:
  • MERS micro-neutralization
Primary collaborators:
  • Lisa E. Hensley, Ph.D. NIH/NIAID/IRF, Ft Detrick, MD. lisa.hensley@nih.gov
# TABLE OF CONTENTS

TABLE OF CONTENTS .................................................................................................................. 3
LIST OF TABLES ......................................................................................................................... 6
LIST OF FIGURES ....................................................................................................................... 6
LIST OF ABBREVIATIONS .......................................................................................................... 7
PROTOCOL SUMMARY ............................................................................................................... 8
PRÉCIS ........................................................................................................................................ 9

1 BACKGROUND INFORMATION AND SCIENTIFIC RATIONALE .......................................... 10
   1.1 Background ...................................................................................................................... 10
   1.2 Rationale ........................................................................................................................ 12

2 STUDY OBJECTIVES ............................................................................................................. 12
   2.1 Primary Objective ........................................................................................................... 12
   2.2 Secondary Objectives ...................................................................................................... 12

3 INVESTIGATIONAL PLAN ................................................................................................... 12
   3.1 General ............................................................................................................................ 12
   3.2 Study Design ................................................................................................................... 12
   3.3 Definitions for the Purpose of this Study ....................................................................... 13

4 STUDY POPULATION ........................................................................................................... 14
   4.1 Research Subject Selection ............................................................................................. 14
   4.2 Recruitment ..................................................................................................................... 14
       4.2.1 Participation of NIH Employees .............................................................................. 14
   4.3 Inclusion Criteria ............................................................................................................ 14
   4.4 Exclusion Criteria ........................................................................................................... 15
   4.5 Justification of Exclusions of Pregnant Women and Children ......................................... 16
       4.5.1 Exclusion of Pregnant and Breastfeeding Women .................................................. 16
       4.5.2 Exclusion of Children ............................................................................................... 16
   4.6 Subject Withdrawal ......................................................................................................... 16
   4.7 Discontinuation of Subject by Investigator ................................................................. 16
   4.8 Discontinuation of Study ............................................................................................... 17
   4.9 Emergency Unblinding ................................................................................................. 17

5 TREATMENT .......................................................................................................................... 17
   5.1 Randomization and Blinding .......................................................................................... 17
   5.2 Formulation, Packaging and Labeling ............................................................................. 18
       5.2.1 SAB-301 .................................................................................................................. 18
       5.2.1.1 Label ................................................................................................................... 18
       5.2.1.2 Storage ................................................................................................................ 18
       5.2.2 Saline Control .......................................................................................................... 18
   5.3 Dosing and Administration ............................................................................................ 18
   5.4 Justification of Dose ...................................................................................................... 20
5.5 Study Drug Accountability ................................................................. 20
5.6 Concomitant Medications .............................................................. 20
5.7 Prohibited Medications ................................................................. 20

6 STUDY PROCEDURES ........................................................................... 20

6.1 Personnel for Study Procedures ......................................................... 20
6.2 Screening .......................................................................................... 20
   6.2.1 Informed Consent ........................................................................ 20
   6.2.2 Demographics ........................................................................... 20
   6.2.3 Medical History ......................................................................... 21
   6.2.4 Clinical Data .............................................................................. 21
   6.2.5 Physical Exam ........................................................................... 21
   6.2.6 Laboratory Testing ..................................................................... 21
   6.2.7 Determination of Eligibility ....................................................... 21

6.3 Detailed Description of Assessments ................................................. 22
   6.3.1 Schedule of Assessments ............................................................ 22
   6.3.2 Location of Study Drug Administration ..................................... 22
   6.3.3 Randomization .......................................................................... 22
   6.3.4 Study Day 0 - Baseline Evaluation ........................................... 23
      6.3.4.1 Interval History and Exam .................................................... 23
      6.3.4.2 Assessment of Baseline Symptoms .................................... 23
      6.3.4.3 Laboratory Testing ............................................................. 23
   6.3.5 Study Day 0: Study Drug Administration .................................... 23
   6.3.6 Study Day 0: Peri-Administration Assessments .......................... 23
   6.3.7 Study Day 1 ............................................................................. 24
      6.3.7.1 Interval History and Exam .................................................... 24
      6.3.7.2 Assessment of Symptoms .................................................. 24
      6.3.7.3 Laboratory Testing ............................................................. 24
   6.3.8 Study Day 3 (+1) ....................................................................... 24
      6.3.8.1 Interval History and Exam .................................................... 24
      6.3.8.2 Assessment of Symptoms .................................................. 24
      6.3.8.3 Laboratory Testing ............................................................. 24
   6.3.9 Study Day 7 (+/-1) ................................................................. 25
      6.3.9.1 Interval History and Exam .................................................... 25
      6.3.9.2 Assessment of Symptoms .................................................. 25
      6.3.9.3 Laboratory Testing ............................................................. 25
   6.3.10 Study Day 21 (+/- 1) ................................................................. 25
      6.3.10.1 Interval History and Exam ................................................... 25
      6.3.10.2 Assessment of Symptoms .................................................. 26
      6.3.10.3 Laboratory Testing ............................................................. 26
   6.3.11 Study Day 42 (+/-2) ................................................................. 26
      6.3.11.1 Interval History and Exam ................................................... 26
      6.3.11.2 Assessment of Symptoms .................................................. 26
      6.3.11.3 Laboratory Testing ............................................................. 26
   6.3.12 Study Day 90 (+/-7) ................................................................. 26
      6.3.12.1 Interval History and Exam ................................................... 26
6.3.12.2 Assessment of Symptoms ................................................................. 27
6.3.12.3 Laboratory Testing .............................................................................. 27

7 MEASURES OF SAFETY, EFFICACY, AND COMPLIANCE .......................... 27
  7.1 Safety Evaluations ..................................................................................... 27
    7.1.1 Laboratory Evaluations ...................................................................... 27
    7.1.2 Physical Examinations ........................................................................ 27
    7.1.3 Vital Signs, Including SaO₂ ................................................................. 28
  7.2 Measures of Pharmacokinetics and Immunogenicity ............................... 28

8 RISKS AND BENEFITS .................................................................................. 28
  8.1 Potential Risks .......................................................................................... 28
    8.1.1 Risks of SAB-301 ............................................................................. 28
    8.1.2 Risk of Intravenous Catheter .............................................................. 31
    8.1.3 Risks of Phlebotomy ......................................................................... 31
  8.2 Potential Benefits ....................................................................................... 31
  8.3 Alternatives ................................................................................................ 31

9 RESEARCH USE OF STORED HUMAN SAMPLES, SPECIMENS, AND DATA .......... 31
  9.1 Intended Use of the Samples/Specimens/Data ........................................... 31
  9.2 Storage of Samples/Specimens/Data ....................................................... 31
  9.3 Storage of Genetic Samples ..................................................................... 31
  9.4 Tracking Samples ....................................................................................... 31
  9.5 Use of Samples/Specimens/Data at the Completion of the Protocol ....... 31
  9.6 Reporting Loss or Destruction of Samples/Specimens/Data .................. 31

10 REMUNERATION PLAN ............................................................................. 32

11 ASSESSMENT OF SAFETY .......................................................................... 33
  11.1 Toxicity Scale .......................................................................................... 33
    11.1.1 Causality ......................................................................................... 33
  11.2 Recording/Documentation ....................................................................... 34
  11.3 Definitions ................................................................................................ 34
  11.4 Adverse Event Reporting ........................................................................ 35
    11.4.1 Expedited Reporting to the NIAID IRB ............................................. 35
    11.4.2 Annual Reporting to the NIAID IRB ............................................... 36
    11.4.3 Investigator Reporting Responsibilities to the Sponsor .................... 36
  11.5 FOLLOW-UP OF ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS .... 36
  11.6 Sponsor’s Reporting Responsibilities ....................................................... 37

12 CLINICAL MONITORING STRUCTURE .................................................. 37
  12.1 Site Monitoring Plan ................................................................................ 37
  12.2 Data and Safety Monitoring ..................................................................... 38
    12.2.1 Investigator Safety Monitoring ....................................................... 38
  12.3 Safety Review and Communications Plan (SRCP) ................................... 38
  12.4 Sponsor Medical Monitor ........................................................................ 38
  12.5 Data and Safety Monitoring Board DSMB ............................................ 38
12.6 Treatment Interruption or Discontinuation ......................................................... 38
12.7 Pausing Rules ................................................................................................. 39
12.8 Dose Escalation Rules .................................................................................... 39
12.9 Statistical Considerations ............................................................................. 40
  12.9.1 Study Size ................................................................................................. 40
12.10 Study Endpoints .......................................................................................... 41
     12.10.1 Primary Endpoint .................................................................................. 41
     12.10.2 Secondary Endpoints ........................................................................... 41
13 ETHICS/PROTECTION OF HUMAN SUBJECTS .................................................. 42
     13.1 Informed Consent Process ....................................................................... 42
     13.2 Subject Confidentiality ............................................................................ 42
14 DATA MANAGEMENT AND MONITORING ...................................................... 42
     14.1 Data Management Responsibilities ......................................................... 42
     14.2 Data Capture Methods ............................................................................ 42
     14.3 Types of Data ........................................................................................... 43
     14.4 Source Documents and Access to Source Data/Documents ..................... 43
     14.5 Record Retention ...................................................................................... 43
15 References ......................................................................................................... 43

LIST OF TABLES
Table 1: Cohorts and Dose Levels ........................................................................... 13
Table 2: Dosing and Administration ...................................................................... 19
Table 3: Schedule of Assessments ....................................................................... 22
Table 4: Compensation Table ............................................................................. 32
Table 5: Adverse Event Rate Table ..................................................................... 41

LIST OF FIGURES
Figure 1: SAB-301 Vial Label ............................................................................... 18
LIST OF ABBREVIATIONS

AE    Adverse Event
ALT   Alanine Aminotransferase
AST   Aspartate Aminotransferase
BMI   Body Mass Index
CBC   Complete Blood Count
CFR   Code of Federal Regulations
CKD-EPI  Chronic Kidney Disease Epidemiology Collaboration
CLIA  Clinical Laboratory Improvement Amendment of 1988
CRF   Case Report Form
CRIS  Clinical Research Information System
CRIMSON  Clinical Research Information Management System of the NIAID
DCR   Division of Clinical Research
DHHS  Department of Health and Human Services
DSMB  Data and Safety Monitoring Board
FDA   Food and Drug Administration
GCP   Good Clinical Practice
GFR   Glomerular Filtration Rate
HAC   Human Artificial Chromosome
hIgG  Human Polyclonal IgG
HIV   Human Immunodeficiency Virus
IBC   Investigator’s Brochure
ICF   Informed Consent Form
ICH   International Conference on Harmonization
IGIV  Immunoglobulin for Intravenous Use
IND   Investigational New Drug
IP    Intrapерitoneal
IRB   Institutional Review Board
IV    Intravenous
K     Potassium
LDH   Lactate Dehydrogenase
MERS  Middle East Respiratory Syndrome
MERS-CoV  Middle East Respiratory Syndrome coronavirus
Na    Sodium
NIAID National Institute of Allergy and Infectious Diseases
NIH   National Institutes of Health
OCRPRO Office of Clinical Research Policy and Regulatory Operations
OHRP  Office for Human Research Protections
OTC   Over-the-Counter
PI    Principal Investigator
PK    Pharmacokinetics
RCHISPP Regulatory Compliance and Human Subjects Protection Program
SAD   Single Ascending Dose
SAE   Serious Adverse Event/Serious Adverse Experience
SRCP  Safety Review and Communication Plan
SUSAR Serious and Unexpected Suspected Adverse Reaction
Tc    Transchromosomic
TKO   Triple Knockout
UP    Unanticipated Problem
UPhonAE Unanticipated Problem that is not an Adverse Event
PROTOCOL SUMMARY

Full Title: A Phase 1, Randomized Double-Blind, Placebo-Controlled, Single Ascending Dose Safety, Tolerability, and Pharmacokinetics Study of SAB-301 in Healthy Adults

Short Title: SAB-301

Clinical Phase: 1

IND Sponsor: OCRPRO/DCR/NIAID/NIH

Conducted by: LIR/NIAID/NIH

Principal Investigator: Richard T. Davey, Jr., MD

Sample Size: 38 subjects

Accrual Ceiling: 70 (up to 70 subjects screened to randomize a total of 38 subjects)

Study Population: Healthy Volunteers aged 18 to 60 years

Accrual Period: Start Date: April 2016  
End Date: December 2016

Study Duration: Start Date: April 2016  
End Date: April 2017

Study Design: Randomized, Double-Blind, Placebo-Controlled, Dose-escalating

Study Agent: Active: SAB-301  
Control: Normal (0.9%) saline

Primary Objective: To evaluate the safety and tolerability of SAB-301 in healthy adults, following single intravenous administration at escalating dose-levels

Secondary Objectives:  
- To evaluate the pharmacokinetics of intravenously administered SAB-301 in healthy adults, following single intravenous administration at escalating dose-levels  
- To determine the ability of serum levels of SAB-301 to neutralize Middle East Respiratory Syndrome (MERS) virus  
- To evaluate the immunogenicity of SAB-301

Primary Endpoint: Type and frequency of adverse events experienced by subjects receiving SAB-301 at escalating dose-levels, as compared to control saline

Secondary Endpoints:  
- Pharmacokinetic profile of intravenously administered SAB-301 in healthy adults  
- MERS virus neutralization assay  
- Frequency and concentrations of antibodies caused by SAB-301, as measured by:  
  - Anti-IgG antibodies using rheumatoid factor  
  - Anti-SAB-301  
  - Anti-Bovine Kappa light chain  
  - Anti-[-] Antibody
PRÉCIS

The administration of convalescent plasma or hyperimmune immunoglobulin is often used for treatment of emerging infectious diseases. However, production of large quantities of anti-pathogen human plasma and/or immunoglobulin with high affinity and avidity antibodies currently requires donations by convalescent humans, a process that can limit availability for a number of reasons. One novel alternative source is transchromosomic (Tc) cattle that produce fully human polyclonal IgG (hIgG) de novo and mount a robust antibody immune response after vaccination.

This study will evaluate the safety, tolerability, and immunogenicity of SAB-301, a fully human polyclonal anti-MERS IgG collected from transchromosomal cattle. Beginning with a low single-dose, subjects are randomized to receive either SAB-301 or a normal saline control, and evaluated on Study Days 1, 3, 7, 21, 42, and 90. The safety and tolerability is evaluated using symptoms, clinical laboratory tests, pharmacokinetics, and immunogenicity assays. Utilizing a series of stopping rules and a medical monitor, the dose will be escalated as safety and tolerability are established.
1 BACKGROUND INFORMATION AND SCIENTIFIC RATIONALE

1.1 Background

Middle East Respiratory Syndrome (MERS) currently has no available treatment. One option for treatment is the use of polyclonal antibodies. Human convalescent plasma and/or immunoglobulins (IGIV) have been used to effectively prevent and treat many viral infections. However, production of large quantities of anti-pathogen human plasma and/or immunoglobulin with high avidity antibodies currently requires donations by people that have recovered from and/or were vaccinated for the disease. The number of people required and the time needed to collect sufficient plasma can limit availability of the final product, especially for rare diseases. One novel alternative source of plasma for manufacturing IGIV is transchromosomic (Tc) cattle that produce fully human polyclonal IgG (hIgG) de novo and mount a robust antibody immune response after vaccination.

A human artificial chromosome (HAC) comprising the entire human Ig gene repertoire (human Ig heavy chain and Human kappa light chain) that resides on 2 different human chromosomes (hChr), specifically the IgH locus from hChr14 and the Igk locus from hChr2, was developed. The system maintains the ability to use the genetic information provided by the immunoglobulin gene repertoires for generating the seemingly unlimited diversity of human polyclonal antibodies (hpAbs). For avoiding the possible human-bovine interspecies incompatibility between the human immunoglobulin mu chain protein (hIgM) and bovine transmembrane α and β immunoglobulins (bIgα and bIgβ) in the pre-B cell receptor complex, the hIgM constant domain was partially replaced with the counterpart of bovine IgM (bIgM) that is involved in the interaction between bIgM and bIgα/bIgβ, to improve the functionality of hIgM in supporting B cell activation and proliferation. Furthermore, the DNA regulatory elements Iγ1 and Sγ1 were bovinized on the HAC to facilitate DNA-protein interactions in the bovine B-cell. This HAC is designated as isKcHACΔ.

This HAC is placed in the germline of cattle with homozygous triple knockouts (TKO) of the 2 bovine Ig mu heavy-chain loci (bIGHM-/- and bIGHML1/-) and the lambda light-chain.

Cattle are able to make IgG, but IgM is part of the B-cell receptor. Without IgM, no IgG is produced. Therefore the IgM knockout strategy functionally limits the ability of the cattle to intrinsically produce bovine IgG. There is a phenomenon in the Tc bovine called “trans-class switch” where the HAC IgG is the IgM on the B-cell. Any “trans-bovine” IgG that is produced has a bovine heavy chain and a human variable region. This is removed in the purification method. The purification protocol removes bovine kappa chimeric IgG to very low levels (less than 1%).

Fully human polyclonal IgG (hIgG/hIgk) can then be produced in high titer in these isKcHACΔ/TKO Tc cattle, and the cattle produce up to 15 g/L of hIgG in the plasma (similar to humans which have 7-16 g/L IgG).

SAB-301 is an anti-MERS IGIV prepared in this system. Purified Al-Hasa strain MERS-CoV S protein nanoparticles are produced by Novavax, Inc. The S protein was chosen because of its
known immunogenicity and antibodies to this protein have been shown to confer a protective response against viral infection. Just prior to immunization of the Tc bovine, an aliquot of the purified S nanoparticles is thawed and mixed with [redacted] and [redacted] adjuvants.

Plasma is collected using an automated plasmapheresis system. After collection of sufficient volume, frozen plasma is thawed, pooled, fractionated by caprylic acid and clarified by depth filtration in the presence of filter aid. The clarified sample containing Tc pAbs are further purified by affinity chromatography, first using an anti-human IgG kappa affinity column to capture Tc pAbs and remove residual non-hIgG and bovine plasma proteins and, second, by passing through an anti-bovine IgG heavy chain specific affinity column to further remove residual IgG molecules that contain a bovine heavy chain. The Tc pAb fraction is then subjected to a Q Sepharose chromatography polishing step to further reduce impurities, nanofiltration, final buffer exchange, concentration and sterile filtration.

SAB-301 has been shown to contain high levels of neutralizing antibodies. Preclinical studies suggest SAB-301 is protective for MERS infection. In mice treated with SAB-301 at 24 hours post-infection, and evaluated at 5 days, MERS-CoV titers were below the level of detection in comparison to that observed with untreated control (p < 0.0001) or with control hIgG-treated mice (p < 0.0001). When SAB-301 was administered 48 hours post-infection, viral titers were reduced ≈1,000 fold by day 5, compared to that observed with untreated control (p < 0.0001) or to control hIgG (p < 0.0001) (1).

Immunogenicity of low levels of chimeric IgG containing bovine kappa light chain (<2.0% of total IgG) and leaked [redacted] antibody ligand fragments from the [redacted] resin (181.4 ppm) was evaluated in Balb/c mice after three dose administrations by intraperitoneal (IP) injections. This study (Report 68-000148) demonstrated after three administrations of SAB-301 to BALB/c mice at 50 mg/kg and 300 mg/kg, the immunogenicity of SAB-301 in the treated mice was mainly caused by human IgG (2+ to 3+) which was expected. Impurities of SAB-301, bovine kappa light chain had weak and [redacted] antibody had minimal to non-detectable immunogenicity in mice. Because of species differences, the occurrence of immunogenicity to bovine kappa light chain and [redacted] antibodies in humans treated with SAB-301 is unknown.

SAB-301 has no binding to human or rabbit tissues in standard tissue cross-reactivity studies (Report A398-14). As SAB-301 is a human IgG, there is no ideal animal for pre-clinical toxicity testing as any animal model will see SAB-301 as a foreign protein. Therefore, the safety or toxicity of SAB-301 in animals may not fully predict the safety or toxicity in humans. With acknowledgment of these limitations, however, the animals used were standard preclinical species. In preclinical toxicity studies in a New Zealand White Rabbits model with doses up to 370 mg/kg, no drug-related effects were observed for clinical observations, body weight, hematology and coagulation parameters, and gross necropsy findings (Report M207-15). All animals survived until their scheduled sacrifices. A 2 and 3.9-fold increase in globulin (GLO) was observed in the males treated with SAB-301 at 50 and 370 mg/kg, respectively, compared with the controls on Day 3. The GLO level was also increased, 1.4- and 4.4-fold, respectively in the females in the 200 and 370 mg/kg groups, compared with the controls. Correlatively, the albumin to globulin ratio was decreased, while total protein was increased in these animals. By Day 50, the globulin, albumin to globulin ratio, and total protein returned to normal after 7
weeks recovery period. The increase in globulin level is considered to be test article-related, but could represent an increase due solely to the presence of SAB-301 in the blood. Evaluation on the plasma drug levels, toxicokinetics, and histopathology are in progress.

1.2 Rationale
This study will be the first in human study of Tc Bovine polyclonal human IGIV, and will evaluate the safety and pharmacokinetics of SAB-301. This will both advance treatments for MERS, as well as establish the safety of a platform that could be used to quickly develop therapeutics for other emerging infectious diseases.

2 STUDY OBJECTIVES

2.1 Primary Objective
- To evaluate the safety and tolerability of SAB-301 in healthy adults, following single intravenous administration at escalating dose-levels

2.2 Secondary Objectives
- To evaluate the pharmacokinetics of intravenously administered SAB-301 using MERS neutralization assays in healthy adults, following single intravenous administration at escalating dose-levels
- To evaluate the immunogenicity of SAB-301

3 INVESTIGATIONAL PLAN

3.1 General
Study size: 38 subjects (up to 70 subjects screened to randomize a total of 38 subjects)
Study duration: 1 year
Study duration of individual subjects (not including screening): 90 days
Sex distribution: males and females
Age range: 18 to 60 years

3.2 Study Design
This safety and tolerability study of intravenous (IV) SAB-301 consists of up to 6 single dose-levels or cohorts (cohort 1–6) in a double-blind, randomized, placebo-controlled dose-escalating cohort design. Six cohorts of 3-10 subjects each will be administered a single IV dose of SAB-301 or saline placebo. At very low doses, the concern is primary allergic or T-cell activation/cytokine storm, so small cohort sizes can be utilized. As the target dose is approached, the sample size will increase to increase the likelihood of detecting toxicity events. The cohorts and dose levels are outlined in Table 1.
Table 1: Cohorts and Dose Levels

<table>
<thead>
<tr>
<th>Cohort</th>
<th>Number of Subjects receiving SAB-301</th>
<th>Number of Subjects receiving Saline Control</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1.0 mg/kg</td>
<td>2.5 mg/kg</td>
</tr>
<tr>
<td>1</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td></td>
<td>2</td>
</tr>
<tr>
<td>3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The administration of the study drug will occur in the day-hospital at the NIH Clinical Center. The number of subjects dosed will follow the limitations below:

- For the first cohort, no more than 1 subject will be dosed on each day.
- For the second cohort, no more than 2 subjects will be dosed on each day.
- For cohort 3-4, no more than 3 subjects will be dosed on each day.
- For cohort 5-6, no more than 3 subjects will be dosed on each day and no more than 6 subjects will be dosed per week.

Beginning with a low single-dose, subjects are randomized to receive either SAB-301 or placebo on Day 0. Subjects are then evaluated on Study Days 1, 3, 7, 21, 42, and 90.

3.3 Definitions for the Purpose of this Study

Definitions for the Purpose of this Study

**Enrolled**
For the purpose of collecting data and samples and reporting AEs, a subject will be considered enrolled beginning from when the informed consent form is signed until the subject is considered “screen failure”, “discontinued”, or “completed”.

**Randomized**
Subjects are considered randomized when they meet all of the following criteria:
- Enrolled (as defined above)
- Confirmation that the inclusion and exclusion criteria are met
- Randomization number is assigned

**Screen Failures**
Subjects are considered screen failures when they meet one or more of the following criteria after signing consent:
- Screening tests reveal that the subject is ineligible.
- Subject withdraws consent before being randomized.
Discontinued
Subjects are considered discontinued when they meet one or more of the following criteria:
- Subject withdraws consent after being randomized and prior to the completion of Day 90 (see Section 4.6).
- Subject is withdrawn after enrollment by Investigator (see Section 4.7) including lost to follow-up.

Completed
Subjects are considered completed when they are followed through Study Day 90 and complete the final study follow-up visit (Study Day 90).

4 STUDY POPULATION

4.1 Research Subject Selection
Healthy volunteers will be recruited for this study.

4.2 Recruitment
Volunteers will be recruited through the posting of advertisements, NIH Clinical Research Volunteer Program, and the Subject Recruitment and Referral Center, and they may include NIH employees. All flyers and advertisements will be submitted to the NIAID IRB for approval.

4.2.1 Participation of NIH Employees
NIH employees may participate in this study, with the following conditions:
- Neither participation nor refusal to participate in this protocol will have any effect on the subject’s employment or work situation.
- A brief medical exam and medical history will be required for participation in this study along with giving blood and urine specimens. To protect the privacy and confidentiality of employee’s participation the employee participant must not work directly for the PI or any of the Associate Investigators on this protocol.

4.3 Inclusion Criteria
1. Age ≥18 years and ≤60 years
2. Body mass index (BMI) of 19-32 kg/m²
3. Estimated glomerular filtration rate ≥70 mL/min at screening, calculated using the CKD-EPI formula
4. Subjects must agree to:
   - Not take any prescription or OTC medications with the exception of acetaminophen, ibuprofen, vitamins, seasonal allergy medications, and/or contraceptive medications for a period 7 days prior to study drug administration (i.e., Day 0)
5. One of the following in order to avoid pregnancy:
• Females who are able to become pregnant (i.e., are not postmenopausal, have not undergone surgical sterilization, and are sexually active with men) must agree to use at least 2 effective forms of contraception from the date of the subject’s signing of the informed consent form through 60 days after the last dose of study drug. At least one of the methods of contraception should be a barrier method.

• Males who have not undergone surgical sterilization and are sexually active with women must agree to use condoms plus have a partner use at least one additional effective form of contraception from the date of the subject’s signing of the informed consent form through 60 days after the last dose of study drug.

4.4 Exclusion Criteria

1. Any history of allergy, anaphylaxis, or severe reaction to beef products (including milk and gelatin)

2. Any history of allergy, anaphylaxis, or severe reaction to IGIV or human blood products

3. Any chronic medical problem that requires daily oral medications (except Tylenol, ibuprofen, oral contraceptives, vitamins, and seasonal allergy medications).

4. History of cardiovascular disease, cardiomyopathy, heart failure, or unexplained syncope

5. Subjects that have had confirmed MERS

6. Women who are breast-feeding

7. Positive urine or serum pregnancy test

8. Abnormal chemistry panel
   • defined as any clinically significant baseline Grade 1 or greater toxicity, or any Grade 3 or greater toxicity (regardless of clinical significance) by the toxicity table
     o evaluating only sodium (Na), potassium (K), serum bicarbonate (total CO2), blood urea nitrogen (BUN), creatinine, glucose, asp (ALT), aspartate aminotransferase (AST), total bilirubin, lactate dehydrogenase (LDH), and estimated glomerular filtration rate (GFR) by the CKD-EPI equation.

9. Abnormal complete blood count (CBC)
   • defined as any clinically significant baseline Grade 1 or greater toxicity, or any Grade 3 or greater toxicity (regardless of clinical significance) by the toxicity table
     o evaluating only the WBC (to include absolute neutrophil, lymphocyte, and eosinophil counts), hemoglobin, hematocrit, and platelets.

10. Abnormal urinalysis
    • defined as any clinically significant baseline Grade 1 or greater toxicity
• evaluating only protein, and RBCs

11. Positive rheumatoid factor
12. IgA deficiency (defined as IgA < 7 mg/dL)
13. Participation in another research study with receipt of any investigational drug within 5 half-lives or 30 days, whichever is longer, prior to study drug administration (i.e., Day 0) and until completion of the study
14. Participation in any other research study for 30 days after study drug administration
15. Receipt of blood products within 2 months prior to study drug administration (i.e. Day 0)
16. Receipt of any vaccination within 30 days prior to study drug administration (i.e. Day 0)
17. Any acute or chronic condition that, in the opinion of the Investigator, would limit the subject’s ability to complete and/or participate in this clinical study

4.5 Justification of Exclusions of Pregnant Women and Children

4.5.1 Exclusion of Pregnant and Breastfeeding Women
Pregnant women are excluded from this study because the effects of SAB-301 on the developing human fetus are unknown with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events (AEs) in nursing infants secondary to treatment of the mother with SAB-301, women that are breastfeeding will also be excluded from the study.

4.5.2 Exclusion of Children
Because there are insufficient data regarding dosing or AEs events available in adults to judge the potential risk in children, children are excluded from this study.

4.6 Subject Withdrawal
Subjects (or their legal surrogates if subjects become unable to make informed decisions) can terminate study participation at any time without prejudice. If a subject terminates participation before completing the study, the reason for this decision will be recorded in the study record.

Best efforts will be made to follow withdrawn subjects who have received study drug administration for safety. Subjects who withdraw from the study after study drug administration will not be replaced.

4.7 Discontinuation of Subject by Investigator
The Investigator has the right to withdraw subjects from the study. Subjects may be withdrawn from the study for any of the following reasons:
• The subject is lost to follow-up.
• The Investigator believes that continuation in the study would be detrimental to the subject. In general, subjects withdrawn for AEs will still be followed for safety follow-up if possible.
• If, in the Investigator’s best judgment, discontinuation is in the subject’s best interest.
The reason for withdrawal from the study is to be recorded in the study record. If a non-serious AE is unresolved at the time of discontinuation, efforts should be made to follow up until the event resolves or stabilizes, the subject is lost to follow-up, or there is some other resolution of the event. The Investigator should make every attempt to follow all SAEs to resolution.

Subjects withdrawn from the study after study drug administration will not be replaced.

4.8 Discontinuation of Study
The National Institute of Allergy and Infectious Diseases (NIAID) Office of Clinical Research Policy and Regulatory Operations (OCRPRO) as the study sponsor, the NIAID Institutional Review Board (IRB), and the Food and Drug Administration (FDA) may terminate this study at any time. Reasons for terminating the study may include, but are not limited to, the following:
- The incidence or severity of an AE in this or other studies indicates a potential health hazard to subjects.
- Subject enrollment is unsatisfactory.
- Data recording is inaccurate or incomplete.
- Investigators do not adhere to the protocol or applicable regulatory guidelines in conducting the study.

4.9 Emergency Unblinding
If a subject experiences a SAE, and the treating clinician requests unblinding of the study treatment, the Principal Investigator (PI) or designee will be contacted. If the PI or designee is in agreement that unblinding is necessary, the PI or designee will contact the NIH Clinical Center Pharmacy for release of the randomization code for the subject to the treating clinician. The sponsor, Medical Monitor, and DSMB will be informed within one business day that unblinding was necessary. In this case, the subject is still considered enrolled in the study, and the data is still used for analysis.

5 TREATMENT

5.1 Randomization and Blinding
A blinded randomization scheme will be generated by the NIH Clinical Center Pharmacy prior to the initiation of the study.

The pharmacy order will be entered into Clinical Research Information System (CRIS), and at this time, the subject will be assigned a randomization code by pharmacy, which is the next unassigned number in the randomization scheme.

Study participants and study team (PI and associate Investigators and study staff) will be blinded throughout the entire study. The study team will be unblinded after the Study Day 90 visit, all laboratory (and immunogenicity) results are available, and the final monitoring visits has occurred.

The infusion will be provided in an opaque bag to obscure the bag, since SAB-301 may develop bubbles similar to what is seen with IGIV, if the product is agitated. This process has been used in other studies (INSIGHT influenza IVIG) and was successful in maintaining blinding of the study team.
5.2 Formulation, Packaging and Labeling

5.2.1 SAB-301

SAB-301 is a purified human immune globulin G (hlgG) polyclonal antibody designed to specifically bind to the MERS-CoV spike (S) protein, a component of the virion membrane that is responsible for binding of the virus to the host cell. The hlgG is purified from the plasma of immunized transchromosomal (Tc) bovines that were immunized with a recombinant MERS spike protein. The vaccine was produced in insect cells. SAB-301 is purified hlgG in a sterile liquid formulated in 10 mM glutamic acid monosodium salt, 262 mM D-sorbitol, 0.05 mg/mL Tween 80, pH 5.5. The drug product will be administered intravenously and will be diluted in saline per the clinical protocol.

5.2.1.1 Label

**Figure 1: SAB-301 Vial Label**

| SAB-301 anti-MERS CoV (Middle East Respiratory Virus) |
| Human Immunoglobulin Intravenous (Tc Bovine-Derived) |
| 74.6mg/ml (671.5mg in 9ml) For Intravenous Use Only |
| Lot No: PD1501231MC Expiry Date: Sept 2017 |
| Store at 2-8°C |
| Mfr: SAB Biotherapeutics, Inc. Sioux Falls, South Dakota, USA |
| Caution: New Drug–Limited by Federal law to investigational use. |

5.2.1.2 Storage

Store SAB-301 at 2-8°C

5.2.2 Saline Control

Subjects randomized to the control infusion will receive normal (0.9%) saline in approximately the same volume as they would have received if randomized to the active arm.

5.3 Dosing and Administration

The NIH clinical center guidelines for administration of a standard human 10% IGIV (10g/100mL) are for the initial rate to be 0.6 mL/kg/hr, and the rate can be increased gradually to a maximum of 4.8 mL/kg/hr, if tolerated.

SAB-301 will be prepared in the following dilutions:

- Cohorts 1&2: will be prepared as a solution 1mg/1ml (0.1% solution by weight), which is 1/100th the concentration of standard human IGIV (e.g. Gammmunex).
- Cohorts 3&4 will be prepared as a solution 4mg/1ml (0.4% solution by weight), which is 1/25th the concentration of standard human IGIV.
- Cohorts 5&6 will be prepared as a solution 20mg/1ml (2% solution by weight), which is 1/5th the concentration of standard human IGIV.

The dose of study drug will calculated based on the subject’s dose cohort and weight (up to a maximum weight of 100 kg). The NIH pharmacy will prepare a bag containing the dose of SAB-301 plus as much normal (0/9%) saline as is needed to reach the above listed concentrations. The infusion will be provided in an opaque bag to obscure the bag (as the
SAB-301 may develop bubbles like IGIV if agitated). The drip chamber will also be covered, but accessible if needed by nursing staff for verification of flow rate, etc.

**Table 2: Dosing and Administration**

<table>
<thead>
<tr>
<th>Cohort</th>
<th>Dose (mg/kg)</th>
<th>Concentration (mg/mL)</th>
<th>Start Rate (mL/kg/hr)</th>
<th>End Rate (mL/kg/hr)</th>
<th>Start Rate (mg/kg/hr)</th>
<th>End Rate (mg/kg/hr)</th>
<th>Proportion of Human IVIG Rate</th>
<th>Duration (mins) (approx.)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>1</td>
<td>1 mg/mL (0.1 %)</td>
<td>0.5</td>
<td>2</td>
<td>0.5</td>
<td>2</td>
<td>1/120th - 1/240th</td>
<td>53</td>
</tr>
<tr>
<td>2</td>
<td>2.5</td>
<td>1 mg/mL (0.1 %)</td>
<td>0.5</td>
<td>3</td>
<td>0.5</td>
<td>3</td>
<td>1/120th - 1/160th</td>
<td>90</td>
</tr>
<tr>
<td>3</td>
<td>5</td>
<td>4 mg/mL (0.4 %)</td>
<td>0.5</td>
<td>2</td>
<td>2</td>
<td>8</td>
<td>1/30th - 1/60th</td>
<td>60</td>
</tr>
<tr>
<td>4</td>
<td>10</td>
<td>4 mg/mL (0.4 %)</td>
<td>0.5</td>
<td>3</td>
<td>2</td>
<td>12</td>
<td>1/30th - 1/40th</td>
<td>85</td>
</tr>
<tr>
<td>5</td>
<td>20</td>
<td>20 mg/mL (2 %)</td>
<td>0.5</td>
<td>1</td>
<td>10</td>
<td>20</td>
<td>1/6th - 1/12th</td>
<td>70</td>
</tr>
<tr>
<td>6</td>
<td>50</td>
<td>20 mg/mL (2 %)</td>
<td>0.5</td>
<td>2</td>
<td>10</td>
<td>40</td>
<td>1/6th - 1/10th</td>
<td>97</td>
</tr>
</tbody>
</table>

The infusion will be started at 0.5 mL/kg/hr, escalating by 0.5 mL/kg/hr increments every 15 minutes to a maximum specified above (end rate).

It is anticipated that the infusion is prepared the morning of the infusion. Since the study drug has been shown stable for 24 hours when mixed in saline, the infusion should be started within 12 hours of preparation in order to assure completion within 24 hours.

The dosing of an individual subject will be slowed and or stopped (depending on clinical assessment) for the following:

- hypotension (systolic or mean blood pressure decreases by 20 mmHg)
- shortness of breath, wheezing, or desaturation
- pain, tenderness, erythema, or swelling around the infusion site.
- fevers, chills
- Other adverse reactions not specified, that are concerning for infusion related adverse events.

After clinical assessment, and resolution or improvement of the event of concern, the infusion may be resumed. If the event is not resolving in a reasonable amount of time, the infusion will not be resumed.

However, in order to establish absolute criteria for stopping – the treatment should be immediately stopped should any of the following occur:

- Profound hypotension (systolic blood pressure < 80 mmHg)
- Severe shortness of breath, wheezing, or sustained (i.e., ≥ 10 seconds) oxygen saturation < 90% on room air
- Severe (Grade ≥ 3) local infusion site reactions, including pain, tenderness, erythema, or swelling as defined in the protocol-specified toxicity grading scale
- Body core temperature exceeding 38.5°C
- Suspected sepsis
- Severe chest pain
- Suspected anaphylaxis
The subject’s actual time of drug administration will be recorded in the source documents.

5.4 Justification of Dose
The starting dose planned is 1 mg/kg, which is 370 times lower than the maximum nonclinical dose of 370mg/kg. The target dose is 50mg/kg. This dose is effective in preclinical models, and is 7.4 times lower than the maximum nonclinical dose, 370mg/kg.

5.5 Study Drug Accountability
The study pharmacist is unblinded, and will maintain accurate drug accountability records. This log will not be shown to the study Investigators. When the study is completed, copies of the study drug accountability records will be returned to the sponsor, and the originals will be maintained at the study site. Copies of the drug accountability records must be maintained with the rest of the documentation for the study. All unused study drug must be disposed of upon authorization by NIAID or its designee. All records regarding the disposition of study drug must be available for inspection by the study monitors and regulatory authorities.

5.6 Concomitant Medications
Subjects will be monitored throughout the study for use of concomitant medications. Any prescription medications, over-the-counter preparations (OTC), herbal remedies, and/or nutritional supplements taken during the study period must be recorded in the research record.

5.7 Prohibited Medications
Subjects will refrain from receipt of any investigational drug within 5 half-lives or 30 days, whichever is longer, prior to Day 0 and during the entire study.

6 STUDY PROCEDURES

6.1 Personnel for Study Procedures
The physical examination (excluding vital signs) will be performed by a physician, nurse practitioner, or physician’s assistant. All other assessments may be performed by other appropriately trained members of the investigative team as noted on the Delegation of Responsibilities form.

6.2 Screening
Screening evaluations may be done up to 4 weeks before Day 0.

6.2.1 Informed Consent
The Investigator will review informed consent with the subject. One informed consent form will be used for both screening and enrollment into this protocol.

6.2.2 Demographics
The following information should be recorded:

- Age
- Sex
- Ethnicity
- Race
6.2.3 Medical History
The following information should be recorded:
- Medical history including any chronic medical conditions
- Current use of prescription and OTC medications within the last 7 days
- History of allergies
- Current or recent participation in any other research protocols

6.2.4 Clinical Data
- Vital signs (See Section 7.1.3)

6.2.5 Physical Exam
A brief physical exam to ensure there are not medical conditions that would increase a subject’s risk for participation in this study (Section 7.1.2)

6.2.6 Laboratory Testing
The following tests will be performed the day of screening:
- CBC with differential
- Reticulocyte count
- PT/PTT
- Chemistry panel
- Quantitative Immunoglobulins
- Routine urinalysis
- Urine biomarkers
- Serum or urine pregnancy test (females of childbearing potential only)
- Rheumatoid factor

(Elements of each panel are listed in Section 7.1.1)

6.2.7 Determination of Eligibility
Once the screening evaluation is complete, eligibility will be determined based on the inclusion and exclusion criteria. Eligible subjects will be contacted, and if still interested in participating, will be scheduled to return to the Clinical Center for randomization and study drug administration. The period of time between screening evaluation visit and administration of study drug should not exceed 4 weeks.

Subjects that are found to be ineligible will be contacted (or told directly if found ineligible during screening evaluation), and the reason for ineligibility will be discussed. If desired by the subject, and if applicable for the reason for ineligibility, the results will be shared with their health care provider and/or the subject will be assisted in finding definitive medical care for said condition.
6.3 Detailed Description of Assessments

6.3.1 Schedule of Assessments

The schedule of assessments is described in Table 3. The day when the subject is randomized is denoted as Study Day 0, the first day after enrollment is Study Day 1, etc.

<table>
<thead>
<tr>
<th>Evaluation/Procedure</th>
<th>Screen</th>
<th>Baseline</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>−28 to 0</td>
<td>0</td>
</tr>
<tr>
<td>Prior to infusion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ELIGIBILITY</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Informed consent</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Demographics</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Medical history</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>RANDOMIZATION/ STUDY DRUG</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Randomize subject</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Study drug administration</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>STUDY PROCEDURES</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Assess Symptoms</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Vital signs</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Review of concomitant medications</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Physical exam</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Adverse events</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>SAFETY LABORATORY*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CBC</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>PT/PTT</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Reticulocyte Count</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Chemistry Panel</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Urinalysis</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Quantitative Immunoglobulin</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Rheumatoid factor</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Urine biomarkers</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Pregnancy test (urine or serum)</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>REFERENCE PROEDURE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stored serum for pharmacokinetics</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Stored serum for immunogenicity</td>
<td>X</td>
<td>X</td>
</tr>
</tbody>
</table>

Notes: a) Elements of each panel are listed in Section 7.1.1
b) PK sample on Day 0 includes baseline (pre-infusion), 1 hour (+/- 15 min) after the end of the infusion, and 6 hours (+/- 30 min) after the end of the infusion.

6.3.2 Location of Study Drug Administration

The study drug will be administered in the day hospital at the NIH. Subjects will be asked to arrive on the unit at least 60 minutes prior to scheduled time of study drug administration.

6.3.3 Randomization

An order for randomization to SAB-301 or placebo will be entered into CRIS. A blinded treatment allocation is determined by the pharmacy as discussed in Section 5.1.
6.3.4 Study Day 0 - Baseline Evaluation
Prior to study drug administration, a baseline evaluation will be performed, including the following:

6.3.4.1 Interval History and Exam
An interval medical history and physical exam will be performed. This will include:
- Any new medical conditions since screening visit
- Any new medications since screening visit
- Allergies
- Participation in any other research protocols within the last month or since the screening visit, whichever is longer

6.3.4.2 Assessment of Baseline Symptoms
The presence of any baseline symptoms will be elicited and documented.

6.3.4.3 Laboratory Testing
The following clinical laboratory tests will be performed and documented:
- CBC with differential
- Reticulocyte Count
- PT/PTT
- Chemistry panel
- Urinalysis
- Urine biomarkers
- Quantitative Immunoglobulins (IgG level)
- Rheumatoid factor
- Serum or urine pregnancy test for women of child-bearing potential
- Stored serum for pharmacokinetics and immunogenicity (16 ml blood)

(Elements of each panel are listed in Section 7.1.1)
Only the pregnancy test must be resulted prior to initiation of study drug infusion.

6.3.5 Study Day 0: Study Drug Administration
SAB-301 or placebo will be prepared as noted in Section 5.3. The blinded bag of SAB-301 diluted in sterile normal saline or placebo (sterile normal saline) will be provided to blinded study staff for dose administration.

A peripheral IV will be placed. The dose will be administered as an IV infusion. For each dose, the subject’s actual administration time will be recorded in the source documents.

6.3.6 Study Day 0: Peri-Administration Assessments
After study drug administration, subjects will remain in the day hospital unit for 6 hours after the end of infusion. The following procedures will occur:
• Vital signs: prior to start of infusion, and then approximately 15 and 30 minutes after the start of the infusion, and every 30 minutes thereafter until the end of the infusion
• Pharmacokinetic Evaluation approximately 1 hour (+/- 15 min) after the end of the infusion. The PK sample (8 ml blood) will be obtained from a separate venipuncture (i.e. not through the infusion IV).
• Vital signs approximately every hour after infusion, and prior to discharge
• Pharmacokinetic Evaluation approximately 6 hours (+/- 15 min) after the end of the infusion. The PK sample (8 ml blood) will be obtained from a separate venipuncture (i.e. not through the infusion IV).
• Any adverse events occurring during the infusion will be recorded

6.3.7 Study Day 1

6.3.7.1 Interval History and Exam
An interval medical history and physical exam will be performed. This will include:
• Any new medical conditions
• Current prescription and OTC medications
• Vital signs
• Physical exam as needed to evaluate new symptoms/complaints

6.3.7.2 Assessment of Symptoms
The presence of any symptoms will be elicited and documented.

6.3.7.3 Laboratory Testing
• Stored serum for pharmacokinetics (8 mL blood)

6.3.8 Study Day 3 (+1)

6.3.8.1 Interval History and Exam
An interval medical history and physical exam will be performed. This will include:
• Any new medical conditions
• Current prescription and OTC medications
• Vital signs
• Physical exam as needed to evaluate new symptoms/complaints

6.3.8.2 Assessment of Symptoms
The presence of any symptoms will be elicited and documented.

6.3.8.3 Laboratory Testing
The following clinical laboratory tests will be performed and documented:
• CBC with differential
• Reticulocyte count
• PT/PTT
• Chemistry panel
• Urinalysis
• Quantitative Immunoglobulins (IgG level)
• Rheumatoid factor
• Urine biomarkers
• Stored serum for pharmacokinetics (8 mL blood)

(Elements of each panel are listed in Section 7.1.1)

6.3.9 Study Day 7 (+/-1)

6.3.9.1 Interval History and Exam
An interval medical history and physical exam will be performed. This will include:
  • Any new medical conditions
  • Current prescription and OTC medications
  • Vital signs
  • Physical exam as needed to evaluate new symptoms/complaints

6.3.9.2 Assessment of Symptoms
The presence of any symptoms will be elicited and documented.

6.3.9.3 Laboratory Testing
The following clinical laboratory tests will be performed and documented:
  • CBC with differential
  • Reticulocyte count
  • PT/PTT
  • Chemistry panel
  • Urinalysis
  • Quantitative Immunoglobulins (IgG level)
  • Rheumatoid factor
  • Urine biomarkers
  • Stored serum for pharmacokinetics & immunogenicity (16 mL blood)

(Elements of each panel are listed in Section 7.1.1)

6.3.10 Study Day 21 (+/- 1)

6.3.10.1 Interval History and Exam
An interval medical history and physical exam will be performed. This will include:
  • Any new medical conditions
  • Current prescription and OTC medications
  • Vital signs
  • Physical exam as needed to evaluate new symptoms/complaints
6.3.10.2 Assessment of Symptoms
The presence of any symptoms will be elicited and documented.

6.3.10.3 Laboratory Testing
The following clinical laboratory tests will be performed and documented:
- Quantitative Immunoglobulins (IgG level)
- Rheumatoid factor
- Stored serum for pharmacokinetics & immunogenicity (16 mL blood)

6.3.11 Study Day 42 (+/- 2)
6.3.11.1 Interval History and Exam
An interval medical history and physical exam will be performed. This will include:
- Any new medical conditions
- Current prescription and OTC medications
- Vital signs
- Physical exam as needed to evaluate new symptoms/complaints

6.3.11.2 Assessment of Symptoms
The presence of any symptoms will be elicited and documented.

6.3.11.3 Laboratory Testing
The following clinical laboratory tests will be performed and documented:
- CBC with differential
- Reticulocyte count
- PT/PTT
- Chemistry panel
- Urinalysis
- Quantitative Immunoglobulins (IgG level)
- Rheumatoid factor
- Urine biomarkers
- Stored serum for pharmacokinetics & immunogenicity (16 mL blood)

Elements of each panel are listed in Section 7.1.1

6.3.12 Study Day 90 (+/- 7)
6.3.12.1 Interval History and Exam
An interval medical history and physical exam will be performed. This will include:
- Any new medical conditions
- Current prescription and OTC medications
- Vital signs
- Physical exam as needed to evaluate new symptoms/complaints
6.3.12.2 Assessment of Symptoms
The presence of any symptoms will be elicited and documented.

6.3.12.3 Laboratory Testing
The following clinical laboratory tests will be performed and documented:
- CBC with differential
- Reticulocyte count
- PT/PTT
- Quantitative Immunoglobulins (IgG level)
- Rheumatoid factor
- Stored serum for pharmacokinetics & immunogenicity (16 mL blood)

7 MEASURES OF SAFETY, EFFICACY, AND COMPLIANCE

7.1 Safety Evaluations

7.1.1 Laboratory Evaluations
All laboratory evaluations (except reference endpoint assays) will be performed at the NIH clinical laboratory (CLIA-certified). Blood samples will be collected from subjects as noted in the schedule of assessments. Abnormal labs thought to be erroneous may be repeated once.

On the designated days, the following laboratory tests will be performed:
- CBC with differential: white cell count (to include absolute neutrophil, and lymphocyte counts), hemoglobin, hematocrit, and platelet count
- Reticulocyte count
- Prothrombin Time (PT) and Partial Thromboplastin Time (PTT)
- Chemistry panel: Na, K, total CO2, BUN, creatinine, glucose, ALT, AST, total bilirubin, LDH, CPK, and estimated GFR by the CKD-EPI equation
- Routine urinalysis (includes protein, glucose, ketones, hemoglobin, urobilinogen, leukocyte esterase, nitrite, pH, specific gravity, RBCs, WBCs)
- Urine biomarkers (quantitative albumin, quantitative protein, β2-microglobulin, and creatinine)
- Serum or urine pregnancy test (females of childbearing potential only)
- Quantitative Immunoglobulins (IgG level)
- Rheumatoid factor

7.1.2 Physical Examinations
A brief physical examination will be conducted at screening to ensure there are no medical conditions that would increase a subject’s risk for participation in this study. Symptom-targeted physical examinations will be conducted at all other visits as needed to evaluate new complaints and possible AEs.
7.1.3 Vital Signs, Including SaO₂
At each visit, vital signs assessments (BP, HR, temperature, respiration rate, oxygen saturation).

7.2 Measures of Pharmacokinetics and Immunogenicity
As noted in the schedule and text above, 8 mL or 16 mL of blood will be obtained for evaluation of pharmacokinetics and immunogenicity. It is anticipated this will be in a serum separator tube (this tube may change without amending the protocol).

Pharmacokinetics evaluations will be performed by SAB Biotherapeutics and Naval Medical Research Center. As SAB-301 cannot be differentiated from human IgG, the pharmacokinetics evaluations will use MERS neutralization assays.

This protocol will evaluate immunogenicity in several assays:
- anti-IgG antibodies using rheumatoid factor (performed at NIH Clinical Center)
- Anti-Drug (anti-SAB-301) Antibody (performed at SAB Biotherapeutics)
- Anti-Bovine Kappa light chain (performed at SAB Biotherapeutics)
- Anti-[Redacted] Antibody (performed at SAB Biotherapeutics)

8 RISKS AND BENEFITS

8.1 Potential Risks
8.1.1 Risks of SAB-301
The risks of SAB-301 are largely unknown. It is anticipated that the risks will be similar to human IGIV with some unique considerations for proteins of animal origin as discussed below.

Based on human IGIV, common side effects may include:
- Headache
- Injection site reaction
- Nausea
- Urticaria
- Fatigue
- Arthralgia
- Pyrexia

Less common side effects may include:
- Vomiting
- Back pain
- Rash

Serious side effects seen with human IGIV that could be seen with SAB-301 include:
- Hyperproteinemia, with resultant changes in serum viscosity and electrolyte imbalances may occur in patients receiving IGIV therapy (2). Humans routinely receive up to 1-2 grams/kg of human-derived IGIV to treat Guillain-Barre syndrome and other immune related neuropathies. Therefore, the addition of 50 mg/kg IgG as SAB-301 is a relatively
small amount and is unlikely to cause AEs related to increased viscosity.

- Aseptic Meningitis Syndrome (AMS) has been reported with IGIV treatments, especially with high doses or rapid infusion. This risk is anticipated to be minimized given the low amount of protein and relatively slow infusion.
- Hemolysis, either intravascular or due to enhanced RBC sequestration, can be seen with human IGIV. This risk is anticipated to be low given the lack of exposure of the cows to RBC antigens.
- Volume overload has been reported with human IGIV. This risk is anticipated to be minimized given the low amount of protein and small total volumes.

There may be unique risks given the animal origin of the IGIV. SAB-301 is a human IgG so it is anticipated the risk with SAB-301 would be less, though there may be residual animal proteins. The most similar product would be an animal polyclonal antibodies to non-human proteins e.g. Horse Heptavalent Botulism Antitoxin.

(http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM345147.pdf)

There is the risk of off-target binding of the IVIG. In the worst case, this could cause immune activation (cytokine storm). The tissue cross reactivity assays do not predict any off target binding, and this has not been seen in any other animal IVIG (of Fab fragment) preparations, so this risk is considered negligible.

For Horse Heptavalent Botulism Antitoxin, the most common adverse reactions in all healthy subjects were headache (9%), pruritus (5%), nausea (5%), and urticaria (5%). Other adverse reactions reported in less than 4% of subjects included pyrexia and throat discomfort. All reported adverse reactions were considered mild or moderate. No serious adverse reactions were reported. Two moderate acute allergic reactions that required premature termination of the infusion and treatment were reported. Reactions were predefined as mild if the subject was aware but could tolerate the symptoms. Moderate reactions were predefined as discomfort enough to interfere with normal daily activity.

The development of antibodies to bovine proteins and potential for food allergies is a theoretical concern. There is precedent for animal antibodies (or Fab fragments) being obtained from animals plasma and given to humans.

- Rabbit Anti-thymocyte Globulin [Thymoglobulin]  
  (http://products.sanofi.ca/en/thymoglobulin.pdf)
- Horse Anti-thymocyte Globulin [Atgamin]  
  (http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM199603.pdf)
- Horse Heptavalent Botulism Antitoxin  
  (http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM345147.pdf)
- Sheep Digoxin Immune Fab [DigiFab]  
  (http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/ucm117626.pdf)
• Sheep Digoxin Immune Fab [DigiBind]
• Sheep Crotalidae Polyvalent Immune Fab [CroFab]
  (http://www.crofab.com/documents/CroFab-Prescribing_Information.pdf)

Upon review of these package inserts, the development of anti-drug antibodies was noted only in Horse Heptavalent Botulism Antitoxin (11 of 271 subjects). There was no warning in any of these products concerning the development of allergies to other animal proteins, nor of any food allergies. As SAB-301 is a transgenic human IgG, the risk should be even further minimized. However given the American diet is often heavy in bovine products (milk and/or beef, including derivatives), there is the risk of development of anti-bovine antibodies that is stimulated with repeated exposure. Given the data above and the lack of precedent for the development of food allergies after exposure to similar products, it is anticipated this risk with SAB-301 is very small.

Patients exposed to topical bovine thrombin products (previously used in surgical procedures e.g. fibrin glue) have developed antibodies towards bovine thrombin and contaminating bovine factor V; these antibodies can cross react with human clotting factors and may cause coagulopathy. [3] In that series, postoperative coagulation abnormalities were more common in patients with antibodies to human coagulation proteins. SAB-301 clinical lots contain less than 5 ppm (parts per million) of bovine plasma proteins, but the clinical significance of this level of bovine contaminants is not known. Regardless, the serial assessment of PT/PTT in the study will monitor for any coagulation abnormalities in the subjects receiving SAB-301.

As SAB-301 is bovine derived, it may contain galactose-alpha-1,3-galactose (alpha-Gal) glycosylation of the IgG. In other products, the alpha-Gal glycosylation has been shown to be the source of immune based hypersensitivity reactions. For example, the epidermal growth factor receptor (EGFR) inhibitor cetuximab is a monoclonal antibody with alpha-Gal glycosylation. Cetuximab, while a marketed product, has been associated with hypersensitivity reactions, including anaphylaxis. In most subjects that had hypersensitivity reaction to cetuximab, IgE antibodies were present in pretreatment samples. [4] This study is designed to start with very small doses, with close monitoring for similar hypersensitivity reactions.

Lastly, SAB’s Tc-bovine production system and the US cattle population have a negligible risk for transmissible bovine spongiform encephalopathy (BSE), also known as “Mad Cow Disease”. Only two reported cases of BSE infection in cows have been documented in the US in the last decade. Risk assessments for infectious diseases were completed on the production herd, and documented procedures are in place to reduce or eliminate certain infectious diseases in the production animals. All inputs (feed, medications, and vaccines) have been evaluated for the transmission of viral and BSE agents. The manufacturing process was also evaluated for the clearance and removal of viruses and BSE. Virus removal has been validated. The BSE Western blot analysis was done to demonstrate clearance and removal of prions.

There may be additional risks not apparent or predicted by preclinical testing.
8.1.2 Risk of Intravenous Catheter
The primary risks of the placement of an intravenous catheter include local discomfort; occasional bleeding or bruising of the skin at the site of needle puncture; hematoma; and, rarely, infection or fainting. To reduce the risk of injury from a fall, the subject will be closely monitored and asked about these symptoms before being allowed to stand up.

8.1.3 Risks of Phlebotomy
The primary risks of phlebotomy include local discomfort, occasional bleeding or bruising of the skin at the site of needle puncture, hematoma and, rarely, infection or fainting. At the time of enrollment and during study visits, each subject will be asked about participation in other research studies, to ensure that blood draws do not exceed 450 mL over any 8-week period for adults, for all research protocols combined.

8.2 Potential Benefits
Subjects will not benefit directly from participation in this protocol.

8.3 Alternatives
As there is no benefit to the subject for enrollment in this protocol, the alternative to participating in this protocol is not to participate.

9 RESEARCH USE OF STORED HUMAN SAMPLES, SPECIMENS, AND DATA

9.1 Intended Use of the Samples/Specimens/Data
Samples and data collected under this protocol will be used to determine the safety and pharmacokinetics of SAB-301.

9.2 Storage of Samples/Specimens/Data
Samples will be stored for the reasons noted above.

9.3 Storage of Genetic Samples
No samples are being stored for genetic testing on the subjects.

9.4 Tracking Samples
Samples will be tracked by a commercial software program.

9.5 Use of Samples/Specimens/Data at the Completion of the Protocol
Samples will be maintained for further laboratory testing for up to 5 years after completion (or closure) of the protocol for the purpose stated in Section 9.1. No long-term storage of samples will occur in this study.

9.6 Reporting Loss or Destruction of Samples/Specimens/Data
Any loss or unanticipated destruction of locally maintained samples (for example, due to freezer malfunction) or data (for example, misplacing a printout of data with identifiers) will be reported to the NIAID IRB.
10 REMUNERATION PLAN

Subjects will be compensated for their time and inconvenience as described in Table 4. Per NIH guidelines time is compensated at the following rate: $20 for the first hour and $10 for each hour or part of an hour thereafter. Subjects will be paid after completion of the study.

Table 4: Compensation Table

<table>
<thead>
<tr>
<th>Activity</th>
<th>Inconv Units</th>
<th>Compensation per visit</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Screening</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinic Visit - 4 hour</td>
<td>50</td>
<td></td>
</tr>
<tr>
<td>Phlebotomy</td>
<td>1</td>
<td>10</td>
</tr>
<tr>
<td></td>
<td></td>
<td>60</td>
</tr>
<tr>
<td><strong>Day 0</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinic Visit - 9 hour</td>
<td></td>
<td>100</td>
</tr>
<tr>
<td>Study Drug Administration</td>
<td>20</td>
<td>200</td>
</tr>
<tr>
<td>Additional Phlebotomy x 2</td>
<td>4</td>
<td>40</td>
</tr>
<tr>
<td></td>
<td></td>
<td>340</td>
</tr>
<tr>
<td><strong>Day 1</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinic Visit - 3 hour</td>
<td></td>
<td>40</td>
</tr>
<tr>
<td>Phlebotomy</td>
<td>1</td>
<td>10</td>
</tr>
<tr>
<td>Additional inconvenience (frequent visits)</td>
<td>4</td>
<td>40</td>
</tr>
<tr>
<td><strong>Day 3</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinic Visit - 3 hour</td>
<td></td>
<td>40</td>
</tr>
<tr>
<td>Phlebotomy</td>
<td>1</td>
<td>10</td>
</tr>
<tr>
<td>Additional inconvenience (frequent visits)</td>
<td>4</td>
<td>40</td>
</tr>
<tr>
<td><strong>Day 7</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinic Visit - 3 hour</td>
<td></td>
<td>40</td>
</tr>
<tr>
<td>Phlebotomy</td>
<td>1</td>
<td>10</td>
</tr>
<tr>
<td>Additional inconvenience (frequent visits)</td>
<td>4</td>
<td>40</td>
</tr>
<tr>
<td><strong>Day 21</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinic Visit - 3 hour</td>
<td></td>
<td>40</td>
</tr>
<tr>
<td>Phlebotomy</td>
<td>1</td>
<td>10</td>
</tr>
<tr>
<td></td>
<td></td>
<td>50</td>
</tr>
<tr>
<td><strong>Day 42</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinic Visit - 3 hour</td>
<td></td>
<td>40</td>
</tr>
<tr>
<td>Phlebotomy</td>
<td>1</td>
<td>10</td>
</tr>
<tr>
<td></td>
<td></td>
<td>50</td>
</tr>
<tr>
<td><strong>Day 90</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinic Visit - 3 hour</td>
<td></td>
<td>40</td>
</tr>
<tr>
<td>Phlebotomy</td>
<td>1</td>
<td>10</td>
</tr>
<tr>
<td>Study completion Bonus (if completes all visits)</td>
<td>200</td>
<td>250</td>
</tr>
</tbody>
</table>

Total for all visits 1020
11 ASSESSMENT OF SAFETY
Regulatory requirements, including FDA regulations and ICH Guideline for Good Clinical Practice, set forth safety monitoring and reporting responsibilities of Sponsors and Investigators to ensure the safety and protection of human subjects participating in clinical trials.

11.1 Toxicity Scale
All AEs that occur during the study should be assessed according to the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table), Version 2.0 (November, 2014).

Some grade 1 laboratory parameters on the DAIDS Toxicity Table fall within the NIH lab reference range for normal values. These normal values will not be reported as grade 1 adverse events.

11.1.1 Causality
Causality (likelihood that the event is related to the study agent) will be assessed considering the factors listed under the following categories:

Definitely Related:
- Reasonable temporal relationship
- Follows a known response pattern
- Clear evidence to suggest a causal relationship
- There is no alternative etiology

Probably Related:
- Reasonable temporal relationship
- Follows a suspected response pattern (based on similar agents)
- No evidence of a more likely alternative etiology

Possibly Related:
- Reasonable temporal relationship
- Little evidence for a more likely alternative etiology

Unlikely Related:
- Does not have a reasonable temporal relationship
  OR
- Good evidence for a more likely alternative etiology

Not Related:
- Does not have a temporal relationship
  OR
- Definitely due to an alternative etiology

Note:
Causality assessment is based on available information at the time of the assessment of the AE. The Investigator may revise the causality assessment as additional information becomes available.

11.2 Recording/Documentation
At each contact with the subject, information regarding AEs will be elicited by appropriate questioning and examinations and will be immediately recorded on a source document. Source documents will include: progress notes, laboratory reports, consult notes, phone call summaries, survey tools, and data collection tools. Source documents will be reviewed in a timely manner by the research team. All reportable AEs that are identified will be recorded in CRIMSON. The start date, the stop date, the severity of each reportable event, and the PI’s judgment of the AEs relationship to the study agent/intervention will also be recorded in CRIMSON.

11.3 Definitions
Adverse Event (AE): Any untoward or unfavorable medical occurrence in a human subject, that includes any abnormal sign (e.g. abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the subject’s participation in the research, whether or not considered related to the research.

Adverse Reaction (AR): An adverse event that is caused by an investigational agent (drug or biologic).

Suspected Adverse Reaction (SAR): An adverse event for which there is a reasonable possibility that the investigational agent caused the adverse event. ‘Reasonable possibility’ means that there is evidence to suggest a causal relationship between the drug and the adverse event. A suspected adverse reaction implies a lesser degree of certainty about causality than an adverse reaction, which implies a higher degree of certainty.

Serious adverse event (SAE): Any adverse event that results in one or more of the following outcomes:
- Death
- Life-threatening (i.e. an immediate threat to life) event
- Inpatient hospitalization or prolongation of existing hospitalization
- Persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions
- Congenital anomaly/birth defect
- Medically important event*

*Medical and scientific judgment should be exercised in deciding whether expedited reporting is appropriate in other situations, such as important medical events that may not be immediately life threatening or result in death or hospitalization, but may jeopardize the subject or may require intervention to prevent one of the other outcomes listed above.

Unexpected Adverse Event: An AE is unexpected if it is not listed in the Investigator’s Brochure or Package Insert (for marketed products) or is not listed at the specificity or severity that has been observed. It is the responsibility of the IND Sponsor to make this determination.
**Serious and Unexpected Suspected Adverse Reaction (SUSAR):** A SUSAR is a suspected adverse reaction that is both serious and unexpected.

**Unanticipated Problem (UP):** Any incident, experience, or outcome that is:
1. Unexpected in terms of nature, severity, or frequency in relation to
   a. The research risks that are described in the IRB-approved research protocol, informed consent document, Investigator’s Brochure, or other study documents; and
   b. The characteristics of the subject population being studied; and
2. Possibly, probably, or definitely related to participation in the research; and
3. Places subjects or others at a greater risk of harm (including physical, psychological, economic, or social harm) than was previously known or recognized. (Per the IND Sponsor, an AE with a serious outcome will be considered increased risk.)

**Unanticipated Problem that is not an Adverse Event (UPnonAE):** An unanticipated problem that does not fit the definition of an adverse event, but which may, in the opinion of the Investigator, involve risk to the subject, affect others in the research study, or significantly impact the integrity of research data.

Protocol Deviation: Any change, divergence, or departure from the IRB-approved study procedures in a research protocol. Protocol deviations are designated serious or non-serious and further characterized as:
1. Those that occur because a member of the research team deviates from the protocol
2. Those that are identified before they occur, but cannot be prevented
3. Those that are discovered after they occur

**Serious Protocol Deviation:** A deviation that meets the definition of a SAE or compromises the safety, welfare, or rights of subjects or others.

**Non-Compliance:** The failure to comply with applicable NIH HRPP policies, IRB requirements, or regulatory requirements for the protection of human subjects. Non-compliance is further characterized as:
1. Serious: Non-compliance that:
   a. Increases risks or causes harm to participants
   b. Decreases potential benefits to participants
   c. Compromises the integrity of the NIH-HRPP
   d. Invalidates the study data
2. Continuing: Non-compliance that is recurring
3. Minor: Non-compliance that is neither serious nor continuing

**11.4 Adverse Event Reporting**

**11.4.1 Expedited Reporting to the NIAID IRB**
Unanticipated problems that are either AEs or non-AEs (as defined by Section 11.3) and Serious Protocol Deviations will be reported within seven calendar days of Investigator awareness. Serious Adverse Events that are possibly, probably, or definitely related to the research will be
reported to the NIAID IRB within seven calendar days of Investigator’s awareness, regardless of expectedness.

11.4.2 Annual Reporting to the NIAID IRB
The following items will be reported to the NIAID IRB in summary at the time of Continuing Review:

- Serious and non-serious unanticipated problems
- SAEs that are possibly, probably, or definitely related to the research
- SAEs that are not related to the research
- All AEs.
- Serious and Non-Serious Protocol deviations
- Serious, continuing, and minor non-compliance
- Any trend or event that, in the opinion of the Investigator, should be reported

11.4.3 Investigator Reporting Responsibilities to the Sponsor
Adverse Events: Line listings, frequency tables, and other summary AE data will be submitted to the IND Sponsor when needed for periodic safety assessments, review of IND annual reports, review of IND safety reports, and in the preparation of final study reports.

SAEs (whether or not they are also UPs) must be reported on the Safety Expedited Report Form (SERF) and sent to the Sponsor Clinical Safety Office (CSO) by fax or e-mail attachment. Deaths and immediately life threatening SAEs must be reported within one business day after the site becomes aware of the event. All other SAEs must be reported within three business days of site awareness.

SPONSOR CLINICAL SAFETY OFFICE CONTACT INFORMATION:

OCRPRO Clinical Safety Office
5705 Industry Lane
Frederick, MD 21704

Phone 301-846-5301
Fax 301-846-6224
E-mail: rchspsafety@mail.nih.gov

Non-Serious AEs that are UPs must also be reported on the SERF and sent to the CSO by fax or e-mail attachment no later than seven calendar days of site awareness of the event. The UPs that are not AEs are not reported to the Sponsor CSO.

Pregnancy: Although pregnancy itself is not an AE, events that meet SAE criteria during pregnancy, delivery, or in the neonate (e.g., congenital anomaly/birth defect) are reportable on the SERF. Pregnancy and pregnancy outcome data (e.g. delivery outcome, spontaneous or elective termination of the pregnancy) will be reported to the CSO within three business days of the site’s awareness via email or fax.

11.5 FOLLOW-UP OF ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS
AEs that occur following enrollment of the subject (by signing the informed consent) are followed until the final outcome is known or until the end of the study follow-up period.

SAEs that have not resolved by the end of the follow-up period are followed until the final outcome is known. If it is not possible to obtain the final outcome for an SAE (e.g. the subject is lost to follow-up), the reason that a final outcome could not be obtained will be recorded by the Investigator on the AE case report form (CRF), if the CRF is still open, and the SERF as applicable.

SAEs that occur after the study follow-up period that are reported to the Investigator and are assessed to be possibly, probably, or definitely related to the study agent must be reported to the CSO, as described above.

11.6  Sponsor’s Reporting Responsibilities

Serious, unexpected, suspected adverse reactions (SUSARs) as defined in 21 CFR 312.32 will be reported to FDA and all participating Investigators as IND Safety Reports. The sponsor will also submit a brief report of the progress of the investigation to the FDA on an annual basis as defined in 21 CFR 312.33.

12  CLINICAL MONITORING STRUCTURE

12.1  Site Monitoring Plan

As per ICH-GCP 5.18 and FDA 21 CFR 312.50, clinical protocols are required to be adequately monitored by the study sponsor. Study monitoring will be conducted according to the “NIAID Intramural Clinical Monitoring Guidelines”. Monitors under contract to the NIAID/OCRPRO will visit the clinical research site to monitor aspects of the study in accordance with the appropriate regulations and the approved protocol. The objectives of a monitoring visit will be:

1) To verify the existence of signed informed consent documents and documentation of the ICF process for each monitored subject;

2) To verify the prompt and accurate recording of all monitored data points and prompt reporting of all SAEs;

3) To compare CRIMSON data abstracts with individual subject records and source documents (subject charts, laboratory analyses and test results, physicians’ progress notes, nurses’ notes, and any other relevant original subject information);

4) To help ensure Investigators are in compliance with the protocol. The monitors also will inspect the clinical site regulatory files to ensure that regulatory requirements (Office for Human Research Protections-OHRP), FDA, and applicable guidelines (ICH-GCP) are being followed. During the monitoring visits, the Investigator (and/or designee) and other study personnel will be available to discuss the study progress and findings of the monitoring visit.

A specific protocol monitoring plan will be discussed with the PI and study staff prior to enrollment. The plan will outline the frequency of monitoring visits based on such factors as study enrollment, data collection status and regulatory obligations.
12.2 Data and Safety Monitoring

12.2.1 Investigator Safety Monitoring

The Investigator or designee may interrupt the administration of study drug to an individual subject, or enrollment into this study if indicated for unanticipated problems or AEs. In addition, the Investigators are responsible for:

- Protecting the safety and welfare of subjects
- Evaluating subject safety, including physician assessment of AEs for seriousness, severity, and causality
- Notifying the sponsor of SAEs and immediately-reportable events
- Providing detailed written reports, including confirmatory tests promptly following immediate initial reports
- Informing the IRB/IEC of SAEs
- Notifying the DSMB of SAEs

12.3 Safety Review and Communications Plan (SRCP)

A Safety Review and Communication Plan (SRCP) has been developed for the protocol. The SRCP is an internal communications document between the PI and the IND Sponsor Clinical Safety Office (CSO), which delineates the safety oversight responsibilities of the PI, the CSO, and other stakeholders. The SRCP also includes the overall plan for conducting periodic safety surveillance assessments.

12.4 Sponsor Medical Monitor

A Medical Monitor representing the IND Sponsor (OCRPRO) has been appointed for oversight of safety in this clinical study. The Sponsor Medical Monitor will be responsible for performing safety assessments as outlined in a Safety Review and Communications Plan (SRCP).

12.5 Data and Safety Monitoring Board (DSMB)

The NIAID Intramural DSMB includes independent experts that do not have direct involvement in the conduct of the study and have no significant conflicts of interests as defined by NIAID policy. The Board will review the study prior to initiation and twice a year thereafter. The Board may convene additional reviews as necessary. The Board will review the study data to evaluate the safety, efficacy, study progress, and conduct of the study. All SAEs, all UPs, and all IND Safety Reports will be reported by the PI to the DSMB at the same time they are submitted to the IRB or IND Sponsor. The PI will notify the DSMB of any cases of intentional or unintentional unblinding as soon as possible. The PI will notify the Board at the time pausing or halting criteria are met and obtain a recommendation concerning continuation, modification, or termination of the study. The PI will submit the written DSMB summary reports with recommendations to the IRB(s).

12.6 Treatment Interruption or Discontinuation

A subject’s study drug infusion may be discontinued at any time at the subject’s request or at the discretion of the Investigator or the Sponsor. The following may be justifiable reasons for the Investigator to discontinue a subject from SAB-301 infusion:
• The subject was erroneously included in the study (i.e., was found to not have met the eligibility criteria)
• The subject experiences an intolerable AE
• The subject is unable to comply with the requirements of the protocol
• The subject participates in another investigational study without the prior written authorization of the Sponsor

The criteria for slowing or stopping a given infusion is discussed in Section 5.3

12.7 Pausing Rules
If any of the following criteria are met at any time the study will be paused to further enrollment until assessed by the medical monitor:
• Any SAE as defined in Section 11.3 that can be possibly, probably, or definitively attributed to the study drug
• Three or more subjects in the same cohort experiencing the same Grade 2 or higher adverse effect that can be possibly, probably, or definitively attributed to the study drug
• Two or more subjects develop the same or clinically similar Grade 3 AE or laboratory abnormality
• Two or more subjects develop a serum creatinine ≥Grade 2 toxicity (≥1.8 mg/dL)
• Two or more subjects develop ≥1.5-fold increase in serum creatinine level from baseline
• Two or more subjects develop GFR <70 mL/min, irrespective if serum creatinine is normal range or Grade 1
• Two or more subjects develop a serum creatinine ≥Grade 2 toxicity in PT and/or PTT (i.e. one grade 2 PT and one grade 2 PTT would meet this pausing rule)

The medical monitor can request information needed (such as a listing of graded AEs and unblinded randomization scheme (directly from the NIH Clinical Center investigational pharmacy group) to evaluate the data. The sponsor medical monitor will ultimately make the decision to either resume the study, ask for formal DSMB review, or stop the study.

If the trial is stopped due to unacceptable adverse events or stopping criteria, the IRB will be notified.

12.8 Dose Escalation Rules
When the results from the Day 7 visit for the last subject in a cohort (e.g., Cohort 1) are available safety parameters will be analyzed to determine the overall safety of that dose-level (e.g., 1 mg/kg). If any of the following criteria are met, the corresponding dose-level is not considered “acceptably safe”, and the study will not proceed to the next higher dose group (as the review is blinded, this will be across treatment arms).
• Any SAE that can be possibly, probably, or definitively attributed to the study drug
• Any immediate hypersensitivity or cytokine storm events
• Two or more subjects with asymptomatic positive anti-IgG (rheumatoid factor)
• One or more subjects with positive anti-IgG (rheumatoid factor) with associated rheumatologic symptoms (i.e. arthralgia, myalgia, etc.)
• Two or more subjects across all cohorts experience the same Grade 3 or higher adverse effect that can be possibly, probably, or definitively attributed to the study drug
• Three of the first 10 subjects (30%) experience the same grade 2 or higher adverse effect that can be possibly, probably, or definitively attributed to the study drug or any time thereafter 30% of enrolled subjects have the same grade 2 or higher ‘related’ AE.
• Two or more subjects across cohorts develop a serum creatinine ≥ Grade 2 toxicity (≥1.8 mg/dL) or doubled from baseline (whichever is lower)

If any of the above criteria are met at any time, then the DSMB will meet to evaluate unblinded study data and make a determination about continuation of the study and/or amendment of the protocol.

12.9 Statistical Considerations

12.9.1 Study Size

It is anticipated that in this study the rate of AEs will be very low in general. In particular, we believe that the chance of experiencing any SAE is less than 1%, while the probability of having any Grade 2 AE is less than 20% and is increasingly less common with more severe AEs. Using the binomial distribution function, Table 5 summarizes the probabilities of observing at least one and at least two subjects having an AE given different AE rates. With the planned sample size, the probability of observing at least one subject with an SAE is 0.08 in the largest cohorts (5 and 6) if the SAE rate is 1%. Therefore, we are unlikely to detect SAEs with such low probability of occurrence. On the other hand, for AEs with 20% probability, we have a good chance of observing at least one AE, and that probability is 0.36 in cohorts 1 and 2, 0.59 in cohorts 3 and 4, and 0.83 in cohorts 5 and 6 (target dose), if the rate of the adverse event is 20%.

The probability of observing an AE in one or two subjects per cohort (N receiving SAB are noted) stratified by the true AE rate is as follows:
Table 5: Adverse Event Rate Table

<table>
<thead>
<tr>
<th>True AE rate</th>
<th>N=2</th>
<th>N=4</th>
<th>N=8</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>&gt;=1</td>
<td>&gt;=2</td>
<td>&gt;=1</td>
</tr>
<tr>
<td>0.01</td>
<td>0.02</td>
<td>0.00</td>
<td>0.04</td>
</tr>
<tr>
<td>0.05</td>
<td>0.10</td>
<td>0.00</td>
<td>0.19</td>
</tr>
<tr>
<td>0.1</td>
<td>0.19</td>
<td>0.01</td>
<td>0.34</td>
</tr>
<tr>
<td>0.15</td>
<td>0.28</td>
<td>0.02</td>
<td>0.48</td>
</tr>
<tr>
<td><strong>0.2</strong></td>
<td><strong>0.36</strong></td>
<td><strong>0.04</strong></td>
<td><strong>0.59</strong></td>
</tr>
<tr>
<td>0.25</td>
<td>0.44</td>
<td>0.06</td>
<td>0.68</td>
</tr>
<tr>
<td>0.3</td>
<td>0.51</td>
<td>0.09</td>
<td>0.76</td>
</tr>
<tr>
<td>0.35</td>
<td>0.58</td>
<td>0.12</td>
<td>0.82</td>
</tr>
<tr>
<td>0.4</td>
<td>0.64</td>
<td>0.16</td>
<td>0.87</td>
</tr>
<tr>
<td>0.45</td>
<td>0.70</td>
<td>0.20</td>
<td>0.91</td>
</tr>
<tr>
<td>0.5</td>
<td>0.75</td>
<td>0.25</td>
<td>0.94</td>
</tr>
<tr>
<td>0.55</td>
<td>0.80</td>
<td>0.30</td>
<td>0.96</td>
</tr>
<tr>
<td>0.6</td>
<td>0.84</td>
<td>0.36</td>
<td>0.97</td>
</tr>
<tr>
<td>0.65</td>
<td>0.88</td>
<td>0.42</td>
<td>0.98</td>
</tr>
<tr>
<td>0.7</td>
<td>0.91</td>
<td>0.49</td>
<td>0.99</td>
</tr>
<tr>
<td>0.75</td>
<td>0.94</td>
<td>0.56</td>
<td>1.00</td>
</tr>
<tr>
<td>0.8</td>
<td>0.96</td>
<td>0.64</td>
<td>1.00</td>
</tr>
<tr>
<td>0.85</td>
<td>0.98</td>
<td>0.72</td>
<td>1.00</td>
</tr>
<tr>
<td>0.9</td>
<td>0.99</td>
<td>0.81</td>
<td>1.00</td>
</tr>
<tr>
<td>0.95</td>
<td>1.00</td>
<td>0.90</td>
<td>1.00</td>
</tr>
</tbody>
</table>

12.10 Study Endpoints

12.10.1 Primary Endpoint

- Type and frequency of AEs experienced by subjects receiving SAB-301 at escalating dose-levels, as compared to placebo

12.10.2 Secondary Endpoints

- Pharmacokinetic profile of intravenously administered SAB-301 in healthy adults
- MERS virus neutralization assay
- Frequency and concentrations of antibodies caused by SAB-301, as measured by:
  - Anti-IgG antibodies using rheumatoid factor
  - Anti-SAB-301
  - Anti-Bovine Kappa light chain
  - Anti-***Antibody***
13 ETHICS/PROTECTION OF HUMAN SUBJECTS

13.1 Informed Consent Process
Informed consent is a process where information is presented to enable persons to voluntarily decide whether or not to participate as a research subject. It is an on-going conversation between the human research subject and the researchers about the essential information about the study, which begins before consent is given and continues until the end of the subject's involvement in the research. Discussions of essential information about the research will include the study's purpose, duration, experimental procedures, alternatives, risks, and benefits. Subjects will have the opportunity to ask questions and have their questions answered.

The participants will sign the informed consent document prior to any procedures being done specifically for the study. The participants may withdraw consent at any time throughout the course of the trial. A copy of the informed consent document will be given to the participants for their records. The researcher will document the signing of the consent form in the subject’s medical record. The rights and welfare of the participants will be protected by emphasizing to them that the quality of their medical care will not be adversely affected if they decline to participate in this study.

13.2 Subject Confidentiality
All records will be kept confidential to the extent provided by federal, state and local law. Study monitors and other authorized representatives of the Sponsor may inspect all documents and records required to be maintained by the Investigator, including but not limited to, medical records. Records will be kept locked and all computer entry and networking programs will be done with coded numbers only. Clinical information will not be released without written permission of the subject, except as necessary for monitoring by IRB, the FDA, the NIAID, the OHRP, or the sponsor’s designee.

14 DATA MANAGEMENT AND MONITORING

14.1 Data Management Responsibilities
The Investigator is responsible for assuring that the data collected is complete, accurate, and recorded in a timely manner. Source documentation (the point of initial recording of information) should support the data collected in the electronic data system, and must be signed and dated by the person recording and/or reviewing the data. All data should be reviewed by the Investigator and signed as required electronic signature.

14.2 Data Capture Methods
Study data will be collected at the study site and maintained in an electronic data system (CRIMSON). This data will be completed on an ongoing basis during the study. Data will be entered into electronic data systems by authorized individuals. Corrections to electronic data systems will be tracked electronically (password protected or through an audit trail) with time, date, individual making the correction, and what was changed.
14.3 Types of Data
Source documents include, but are not limited to, the subject’s medical records, laboratory reports, ECG tracings, x-rays, radiologist’s reports, subject’s diaries, biopsy reports, ultrasound photographs, progress notes, pharmacy records, and any other similar reports or records of procedures performed during the subject’s participation in the study.

14.4 Source Documents and Access to Source Data/Documents
Source documents include all recordings of observations or notations of clinical activities, and all reports and records necessary for the evaluation and reconstruction of the clinical trial. Data from CRIMSON Data System will be collected directly from subjects during study visits and telephone calls, or will be abstracted from subjects’ medical records. The subject’s medical record must record his/her participation in the clinical trial and, after unblinding, study treatment/vaccination (with doses and frequency) or other medical interventions or treatments administered, as well as any adverse reactions experienced during the trial.

14.5 Record Retention
The Investigator is responsible for retaining all essential documents listed in the ICH Good Clinical Practice Guideline. All essential documentation for all study subjects are to be maintained by the Investigators in a secure storage facility for a minimum of three years per NIAID policies. The FDA requires study records to be retained for up to two years after marketing approval or disapproval (21 CFR 312.62), or until at least two years have elapsed since the formal discontinuation of clinical development of the investigational agent for a specific indication. These records are also to be maintained in compliance with IRB/EC, state, and federal medical records retention requirements, whichever is longest. All stored records are to be kept confidential to the extent required by federal, state, and local law.

Should the Investigator wish to assign the study records to another party and/or move them to another location, the Investigator must provide written notification of such intent to OCRPRO/NIAID with the name of the person who will accept responsibility for the transferred records and/or their new location. NIAID must be notified in writing and written NIAID/OCRPRO permission must be received by the site prior to destruction or relocation of research records.

15 REFERENCES

